All News
Lupus has many flavors. If we are better able to sort them, we might be more better at finding effective treatments. @rheumnow #RNL2024 @DrDavidKarp https://t.co/rklqnA8Ur6
TheDaoIndex KDAO2011 ( View Tweet)
"SLE affects women in the prime of their life, 25% of pts go to the ER, up to 50% will have lupus nephritis; it is a deadly and costly disease.” - @DrDavidKarp on why we would be focusing on identifying preclinical SLE and preventing the disease #RNL2024 @rheumnow https://t.co/SIZ5ZBwu94
TheDaoIndex KDAO2011 ( View Tweet)
Should we define preclinical SLE as stages rather than using confusing nomenclatures like UCTD, incomplete lupus, etc? - @DrDavidKarp @rheumnow #RNL2024 https://t.co/OjRjdBzJWE
TheDaoIndex KDAO2011 ( View Tweet)
When should you intervene? We talk about primary and secondary prevention... but what about primordial prevention that targets social determinants of health? - @drdavidkarp #RNL2024 @rheumnow https://t.co/UGAcNFLqZf
TheDaoIndex KDAO2011 ( View Tweet)
What early biomarkers are specific for SLE? How many will progress to stage 2? Who should we screen? Will patients revert to pre-stage 1? Is progression preventable? @DrDavidKarp on relevant questions we need to ask regarding preclinical stage 1 lupus. #RNL2024 @rheumnow https://t.co/bJPG68WdyE
TheDaoIndex KDAO2011 ( View Tweet)
Can HCQ prevent SLE? Results of the MONA-LISA study is being analyzed (pts have +ANA and 1-2 SLICC criteria for SLE randomized to PCB or HCQ) - @DrDavidKarp @rheumnow #RNL2024 https://t.co/9yoFXS7wMe
TheDaoIndex KDAO2011 ( View Tweet)
#RNL2024 @RheumNow
@DrDavidKarp
Incomplete lupus is heterogeneous term
"Stage 2" pre-classification stage as ILE/UCTD
Stage 1: non-specific antibodies, dysregulation
2: incomplete features
3: classified, multi-system disease
4: irreversible tissue damage https://t.co/CuLUzSZ24E
Links:
Eric Dein ericdeinmd ( View Tweet)
@reumacia @RheumNow You are absolutely right. The point was not generally used for psoriasis ( not PsA). I was surprised my self 🤕.
Here is the slide again by Dr. Armstrong , great talk by the way. Let me know if you want the handout. https://t.co/C11Gkn2jho
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Appreciative inquiry in rheumatology and how to enhance and improve our clinical notes to frame our encounter in a positive manner.
@BharatKumarMD
#RNL2024
@RheumNow https://t.co/iTXwjUb6tg
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Some takeways from JAK inhibitors in dermatology talk by Bruce Strober.
Great talk.
#RNL2024
@RheumNow https://t.co/fuRsSnnsha
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Alopecia aerate and JAK
Bruce Strober
#RNL2024
@RheumNow https://t.co/lGig1Vpf5x
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Examples from the world of dermatology on JAK inhibitor success stories.
Bruce storber.
#RNL2024
@RheumNow https://t.co/S01lEIqjbR
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dermatology colleagues are using JAKis with success for wide range of dermatological diseases.
Note the beauty of this slide with further elaboration on domain inhibition, cool stuff 🤓
Bruce Strober
#RNL2024
@RheumNow https://t.co/2yHHcOgTC8
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Allosteric versus active site inhibition by JAK.
Never understood this better.
Thanks to Bruce Strober.
#RNL2024
@RheumNow https://t.co/r9hhHLO5oS
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
JAK safety and malignancy risk.
Great talk by kevin Winthrop.
#RNL2024
@RheumNow https://t.co/d7WRHJxrpM
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
@BharatKumarMD at #RNL2024 @RheumNow
Appreciative Inquiry in Rheumatology
5(ish) steps
Dawn (what focus on) -> Discovery (what gives life) -> Dream (what might be) -> Design (what should be) -> Destiny (how can i execute) -> New Dawn
- Empathy at center of inquiry https://t.co/gDhXpi94pT
Eric Dein ericdeinmd ( View Tweet)
JAK toxicity of interest.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/qdlJFKTUR8
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Unique and selective allosteric mechanism of deucravacitinib.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/Zm3bYGR9JJ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Disease activity indices may perform differently in man and women.
@lihi_eder
#RNL2024
@RheumNow https://t.co/8G1D0pGKe8
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Diagnostic delay in SpA
2.3 years longer delay in diagnosis in women with PsA.
@lihi_eder
#RNL2024
@RheumNow https://t.co/d9ao8vvpa5
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)